Morrison & Foerster advised lead investors ARCH Venture Partners and GV in connection with a Series A financing round for $50 million in newly-launched Rome Therapeutics, a Cambridge, Mass.-based biotechnology startup leveraging repeatome for drug development.
ROME Therapeutics was founded to discover and develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome. Its long-term goal is to find new drugs that drive cancer and autoimmune diseases into sustained remission.
The MoFo deal team was led by Boston-based corporate partner Ori Solomon, co-chair of the firm’s Emerging Companies + Venture Capital Group, and included ECVC of counsel Lee Shepard and associate Shiri Shenhav, and executive compensation partner Ron Aizen.
Read the press release.